The neuropeptide substance P regulates aldosterone secretion in human adrenals

• Published in: Nature communications 2020-05, Vol.11 (1), p.2673-2673, Article 2673
• Main Authors: Wils, Julien, Duparc, Céline, Cailleux, Anne-Françoise, Lopez, Antoine-Guy, Guiheneuf, Caroline, Boutelet, Isabelle, Boyer, Hadrien-Gaël, Dubessy, Christophe, Cherifi, Saloua, Cauliez, Bruno, Gobet, Françoise, Defortescu, Guillaume, Ménard, Jean-François, Louiset, Estelle, Lefebvre, Hervé
• Format: Article
• Language: English
• Subjects: 13; 13/106; 13/51; 38; 38/77; 631/443; 692/163; 82/80; 96; 96/95; Adolescent; Adrenal Cortex - metabolism; Adrenal Glands - metabolism; Adrenocorticotropic hormone; Adult; Aldosterone; Aldosterone - blood; Aldosterone - metabolism; Angiotensin; Aprepitant - pharmacology; Autonomic nervous system; Blood pressure; Cells, Cultured; Clinical trials; Endocrinology and metabolism; Extracellular signal-regulated kinase; Homeostasis; Human health and pathology; Humanities and Social Sciences; Humans; Hydrocortisone; Hypoglycemia; Hypoglycemia - blood; Kinases; Life Sciences; Male; Metoclopramide; Mineralocorticoids - biosynthesis; multidisciplinary; Neurobiology; Neurokinin; Neurokinin-1 Receptor Antagonists - pharmacology; Neurons and Cognition; Neuropeptides; Parkinson's disease; Placebos - administration & dosage; Plasma; Posture; Potassium; Proof of Concept Study; Prospective Studies; Receptors; Receptors, Neurokinin-1 - metabolism; Regulatory mechanisms (biology); Renin; Science; Science (multidisciplinary); Secretion; Sodium; Substance P; Substance P - metabolism; Transaminase; Transaminases - blood; Young Adult
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-020-16470-8

Aldosterone, produced by the adrenals and under the control of plasma angiotensin and potassium levels, regulates hydromineral homeostasis and blood pressure. Here we report that the neuropeptide substance P (SP) released by intraadrenal nerve fibres, stimulates aldosterone secretion via binding to neurokinin type 1 receptors (NK1R) expressed by aldosterone-producing adrenocortical cells. The action of SP is mediated by the extracellular signal-regulated kinase pathway and involves upregulation of steroidogenic enzymes. We also conducted a prospective proof-of-concept, double blind, placebo-controlled clinical trial aimed to investigate the impact of the NK1R antagonist aprepitant on aldosterone secretion in healthy male volunteers (EudraCT: 2008-003367-40, ClinicalTrial.gov: NCT00977223). Participants received during two 7-day treatment periods aprepitant (125 mg on the 1 st day and 80 mg during the following days) or placebo in a random order at a 2-week interval. The primary endpoint was plasma aldosterone levels during posture test. Secondary endpoints included basal aldosterone alterations, plasma aldosterone variation during metoclopramide and hypoglycaemia tests, and basal and stimulated alterations of renin, cortisol and ACTH during the three different stimulatory tests. The safety of the treatment was assessed on the basis of serum transaminase measurements on days 4 and 7. All pre-specified endpoints were achieved. Aprepitant decreases aldosterone production by around 30% but does not influence the aldosterone response to upright posture. These results indicate that the autonomic nervous system exerts a direct stimulatory tone on mineralocorticoid synthesis through SP, and thus plays a role in the maintenance of hydromineral homeostasis. This regulatory mechanism may be involved in aldosterone excess syndromes. Adrenal aldosterone production is regulated by plasma angiotensin and potassium levels. Here the authors report that the neuropeptide substance P stimulates aldosterone production via neurokinin type 1 receptors (NK1R), and report a proof-of-concept placebo controlled clinical trial showing that a NK1R antagonist decreases aldosterone levels.